Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (241-250 of 317) with videos related to

Pageof 32
Sort By:
International Journal of Cancer|February 27, 2023
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trialsMelissa M de Meza, Willeke A M Blokx, Han J Bonenkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Annals of Internal Medicine|February 15, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort StudyMonique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts, et al.
Cancers|January 21, 2023
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome AnalysisMelissa M De Meza, Willeke A M Blokx, Johannes J Bonenkamp, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with responseMark Schuiveling, Isabella A J van Duin, Laurens S Ter Maat, et al.
Cancers|July 31, 2020
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and ResponseMonique K van der Kooij, Marjolein J A L Wetzels, Maureen J B Aarts, et al.
Nature Cancer|April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Cancers|October 23, 2021
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The NetherlandsJesper van Breeschoten, Alfonsus J M van den Eertwegh, Liesbeth C de Wreede, et al.
Pageof 32

Showing results (241-250 of 317) with videos related to

Sort By:
Pageof 32
International Journal of Cancer|February 27, 2023
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trialsMelissa M de Meza, Willeke A M Blokx, Han J Bonenkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Annals of Internal Medicine|February 15, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort StudyMonique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts, et al.
Cancers|January 21, 2023
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome AnalysisMelissa M De Meza, Willeke A M Blokx, Johannes J Bonenkamp, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with responseMark Schuiveling, Isabella A J van Duin, Laurens S Ter Maat, et al.
Cancers|July 31, 2020
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and ResponseMonique K van der Kooij, Marjolein J A L Wetzels, Maureen J B Aarts, et al.
Nature Cancer|April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Cancers|October 23, 2021
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The NetherlandsJesper van Breeschoten, Alfonsus J M van den Eertwegh, Liesbeth C de Wreede, et al.
Pageof 32